27/03/2000
The Cambridge-based biotech outfit is selling Mimetrix, its drug discovery arm, to Medivir, a Swedish-listed biotech firm. The consideration of £2m in Medivir shares and up to £4m cash in milestone and royalty payments is dependent on a fundraising planned for April. The deal also involves a service agreement which will see Medivir pay Peptide for use of the facilities and support staff. Following the sale, Peptide will be focused purely on vaccines.
| Market cap: | £67.8m |
| PE Average: | 45.1 |
| PE Forecast: | n/a |
| PE Historic: | n/a |
| Share price: | 68.5p |
| LSE | 0pm |
p
|
p
|
|
| Other company articles: |
| 21/01/2008 |
| 01/04/2003 |
| 01/05/2002 |
| 02/04/2002 |
| 29/11/2001 |
Agency Commercial Mortgage
Looking for Agency Commercial Mortgage? Search over 15,000 sites with one click. Your source for everything under the sun.
Agency Commercial Mortgage - Check Out I Found It
All the top companies and links for agency commercial mortgage under one roof at I-Found-It.
